Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 9, 2018 (9 years ago)

Ibuprofen Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.

Affected NDC 25000-0117-30

Compare with the code on your package — it is the most precise check available.

Drug: Ibuprofen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ibuprofen
NDC 25000-0117
200 mg/1 Tablet
Oral
Marksans Pharma Limited OTC
Recalling firm
Marksans Pharma Inc.
NDC code
25000-117-30
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0235-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ibuprofen recalls

See all
Class II · Moderate risk

Advil a) Ibuprofen

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0261-2026
Class III · Low risk

IBU (ibuprofen)

Failed Tablet/Capsule Specifications

Ongoing Failed specification Dr. Reddy's Laboratories, Inc. NDC 55111-683-05 D-0047-2025
Class II · Moderate risk

Ibuprofen 800mg

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

Ongoing Impurity / degradation Direct Rx NDC 61919-0621-15 D-0041-2025

Other recalls by Marksans Pharma Inc.

All 2018 recalls
Class II · Moderate risk

Time-Cap Labs

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Terminated Nitrosamine impurity Marksans Pharma Limited NDC 49483-624-01 D-0062-2021
Class II · Moderate risk

Time-Cap Labs

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Terminated Nitrosamine impurity Marksans Pharma Limited NDC 49483-623-09 D-0061-2021
Class II · Moderate risk

Time-Cap Labs

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Terminated Nitrosamine impurity Marksans Pharma Limited NDC 49483-623-01 D-1356-2020
Class II · Moderate risk

Ibuprofen Tablets

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Terminated cGMP deviation Marksans Pharma Inc. NDC 25000-123-27 D-0240-2018